Apogen Biotechnologies: Accelerator Corp. launches ApoGen with $7M round to slow cancer drug resistance

Seattle biotech investment and management firm Accelerator Corp. has launched startup ApoGen Biotechnologies through a $7 million Series A round. Seattle-based ApoGen will use the financing to develop a new class of drugs to slow or stop cancer cells' ability to develop drug resistance. "One of the great challenges in treating cancer is that it evolves over time and develops resistance to therapy," said ApoGen CEO Thong Q. Le, who is also Accelerator's CEO. "ApoGen's drug discovery and...